GALC

Galactocerebrosidase · P54803 · GALC on Sugi Atlas →

0 patent compounds predicted against GALC, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to GALC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease PHASE3COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease PHASE1/PHASE2SUSPENDED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia PHASE1/PHASE2NOT_YET_RECRUITING
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Krabbe Disease Global Patient Registry nanRECRUITING
Registry Gangliosidoses nanUNKNOWN
Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease nanCOMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD) nanWITHDRAWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C nanUNKNOWN
The Natural History of Infantile Globoid Cell Leukodystrophy nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Biomarkers Related to Bone in Pediatric Gaucher Disease nanUNKNOWN
Italian Anderson Fabry Disease Cardiovascular Registry nanRECRUITING
Effect of Migalastat on Cardiac Involvement in Fabry Disease nanCOMPLETED
Assessment of Neurological Manifestations in Gaucher Disease Patients nanUNKNOWN
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity nanCOMPLETED
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease nanNO_LONGER_AVAILABLE
Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies nanCOMPLETED
Early Detection and Follow-Up of Patients With Fabry's Disease nanUNKNOWN
Biomarker for Patients With Fabry Disease (BioFabry) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a GALC binder may also engage these)

ProteinNameSimilarity
O02791 1.000 O02791 →
P54804 1.000 P54804 →
Q0VA39 0.998 Q0VA39 →
P54818 0.997 P54818 →
Q498K0 0.997 Q498K0 →
Q5SNX7 0.990 Q5SNX7 →
B5X3C1 0.990 B5X3C1 →
Q8GX69 0.981 Q8GX69 →
P45582 0.979 P45582 →
Q9FF10 0.976 Q9FF10 →
Q9MAJ7 0.976 Q9MAJ7 →
Q6ZJJ0 0.976 Q6ZJJ0 →
Q9SCV9 0.976 Q9SCV9 →
Q9FFN4 0.976 Q9FFN4 →
P48980 0.975 P48980 →
Q9WTZ2 0.975 Q9WTZ2 →
Q10RB4 0.975 Q10RB4 →
O35298 0.974 O35298 →
Q9SCV3 0.974 Q9SCV3 →
Q9SCV4 0.973 Q9SCV4 →
Q9FZP1 0.973 Q9FZP1 →
Q9SCV0 0.973 Q9SCV0 →
Q9SCW1 0.973 Q9SCW1 →
Q75HQ3 0.973 Q75HQ3 →
Q6Z6K4 0.973 Q6Z6K4 →
P48981 0.973 P48981 →
Q9LFA6 0.973 Q9LFA6 →
Q6DE40 0.972 Q6DE40 →
Q9SCV8 0.972 Q9SCV8 →
Q60HF6 0.972 Q60HF6 →